News & Updates

A recent study has raised the possibility of removing surgery in the management of nonmetastatic breast cancer patients with a complete clinical response (cCR) to neoadjuvant chemotherapy (NACT).

The use of tocilizumab (TCZ) shows efficacy in the treatment and prevention of immune checkpoint inhibitor (ICI)-associated arthritis (AR) upon ICI rechallenge, according to a study.

Treatment with abemaciclib, either alone or in combination with fulvestrant, results in improved overall (OS) and progression-free survival (PFS) in patients with HR+/HER2– advanced or metastatic breast cancer, as shown in a recent study.

A single-pill combination that contains albendazole and ivermectin is superior to albendazole alone for treating Trichuris trichiura and hookworm infections, with similar safety profiles, according to data from a phase II/III trial.

Among patients with inflammatory bowel disease (IBD), treatment with Janus kinase inhibitors (JAKi) does not increase the risk of major adverse cardiovascular events (MACE) compared with tumour necrosis factor inhibitors (TNFi), according to a study presented at AIBD 2024.

First-line treatment with erlotinib, gefitinib, and osimertinib demonstrates safety and efficacy in patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), suggests a study.

People with gallstone disease are at higher risk of inflammatory bowel disease (IBD), regardless of other traditional risk factors, according to a study.